Diagnostic value of plasma HSP90? levels for detection of hepatocellular carcinoma.

ABSTRACT: BACKGROUND:Hepatocellular carcinoma (HCC) is a major health problem worldwide. However, the popular tumor marker, AFP, lacks sensitivity although its specificity is high. Tissue biopsy is an invasive operation and may increase the risk of needle-track metastases. Heat shock protein 90 (HSP90) is a potential biomarker for tumor diagnosis and prognosis. This study aims to determine whether levels of plasma HSP90? in HCC patients can be used as a cost-effective and simple test for the initial diagnosis of the disease. METHODS:Plasma samples were collected from 659 HCC patients, 114 secondary hepatic carcinoma (SHC) patients, 28 hepatic hemangioma patients and 230 healthy donors. The levels of HSP90? were measured by ELISA. RESULTS:The levels of plasma HSP90? in HCC patients were significantly higher than in healthy donors and in patients with hepatic hemangioma or SHC (144.08?±?4.98, 46.81?±?1.11, 61.56?±?8.20 and 111.96?±?10.08?ng/mL, respectively; p 

SUBMITTER: Wei W 

PROVIDER: S-EPMC6941289 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature